Summary
EudraCT Number: 2006-006436-22
Sponsor's Protocol Code Number: BAY a1040/12313
National Competent Authority: Spain - AEMPS 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2007-07-13
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006436-22/ES/

A. Protocol Information
A.1 Member State Concerned: Spain - AEMPS
A.2 EudraCT number: 2006-006436-22
A.3 Full title of the trial: Estudio multicéntrico para evaluar la eficacia de la combinación nifedipino GITS - telmisartan en el control de la presión arterial y otros párámetros: comparación de dos estrategias terapéuticas.
A.3.2 Name or abbreviated title of the trial where available: TALENT
A.4.1 Sponsor's protocol code number: BAY a1040/12313
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: Bayer SpA
B.1.3.4	Country: Italy
B.3.1 and B.3.2	Status of the sponsor: Non-Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Adalat Crono
D.2.1.1.2 Name of the Marketing Authorisation holder: Bayer S.p.A., Italy
D.2.1.2 Country which granted the Marketing Authorisation: Italy
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Nifedipine GITS
D.3.4 Pharmaceutical form: Prolonged-release tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Nifedipine
D.3.9.2 Current sponsor code: Nifedipine GITS (BAY a 1040)
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 20 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Pritor 80 mg
D.2.1.1.2 Name of the Marketing Authorisation holder: BayerHealthCare AG, Germany
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: telmisartan
D.3.4 Pharmaceutical form: Tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Telmisartan
D.3.9.2 Current sponsor code: Telmisartan (BAY 68-9291)
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 80 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 3
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Adalat Oros
D.2.1.1.2 Name of the Marketing Authorisation holder: Quimica Farmaceutica Bayer, S.L.
D.2.1.2 Country which granted the Marketing Authorisation: Spain
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Nifedipino GITS
D.3.4 Pharmaceutical form: Prolonged-release tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Nifedipine 
D.3.9.2 Current sponsor code: Nifedipine GITS (BAY a 1040)
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 30 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 4
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Pritor 80 mg
D.2.1.1.2 Name of the Marketing Authorisation holder: Bayer HealthCare AG, Germany
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Telmisartan
D.3.4 Pharmaceutical form: Tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: telmisartan
D.3.9.2 Current sponsor code: Telmisartan (BAY 68-9291)
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 80 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 5
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Adalat Crono
D.2.1.1.2 Name of the Marketing Authorisation holder: Bayer S.p.A., Italy
D.2.1.2 Country which granted the Marketing Authorisation: Italy
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Nifedipine GITS
D.3.4 Pharmaceutical form: Prolonged-release tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Nifedipine
D.3.9.2 Current sponsor code: Nifedipine GITS (BAY a 1040)
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 20 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1 Is a Placebo used in this Trial? Yes
D.8.3 Pharmaceutical form of the placebo: Prolonged-release tablet
D.8.4 Route of administration of the placebo: Oral use
D.8 Placebo: 2
D.8.1 Is a Placebo used in this Trial? Yes
D.8.3 Pharmaceutical form of the placebo: Tablet
D.8.4 Route of administration of the placebo: Oral use

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: hipertensión
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 9.1
E.1.2 Level: LLT
E.1.2 Classification code: 10020772
E.1.2 Term: Hypertension
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: El objetivo principal de este estudio es evaluar la eficacia en el control de la presión arterial cuando el tratamiento antihipertensivo se inicia con una combinación Nifedipino GITS en bajas dosis y Telmisartán en comparación con un régimen que se inicia con monoterapia antes de añadir otro fármaco.
E.2.2 Secondary objectives of the trial: También se evaluará el efecto del tratamiento sobre los marcadores metabólicos y de  inflamación como indicadores del riesgo cardiovascular.
E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria: En la Visita de Selección:
-Hipertensión (presión arterial sistólica > 135 mmHg en  la consulta), no tratada o mal controlada a pesar de un régimen antihipertensivo estable durante ≥ 4 semanas
-Presencia de diabetes mellitus tipo 2 o lesión del órgano diana (hipertrofia ventricular izquierda por ecocardiografía o electrocardiografía o microalbuminuria)
-Presencia de síndrome metabólico, es decir, al menos dos de los siguientes:
    (a) alteración de la tolerancia a la glucosa (glucemia basal 110 -125 mg/dl)
    (b) hipertrigliceridemia ( ≥ 150 mg/dl)
    (c)bajas concentraciones de colesterol HDL (varones: < 40 mg/dl, mujeres: < 50 mg/dl)
    (d)perímetro de la cintura > 102 cm en los hombres y > 88 cm en las mujeres
-Edad: 18-75 años.
-Prueba de embarazo negativa.
-Consentimiento informado por escrito.

E.4 Principal exclusion criteria: -Tratamiento actual con los siguientes fármacos: inhibidores de la ECA (p. ej., captopril, benazepril, enalapril, lisinopril, fosinopril, ramipril, perindopril, quinapril, moexipril y trandolapril), antagonistas de la AT1 (p. ej., losartán, candesartán, eprosartán, telmisartán) o calcioantagonistas (p. ej., amlodipino, felodipino, isradipino, nifedipino, nimodipino) y que no pueda suspenderse.
-Tratamiento concomitante con otros antihipertensivos que no se pueden suspender de forma segura al entrar en el estudio.
-Tratamiento concomitante con inhibidores conocidos del citocromo P450-3A4 (p. ej., cimetidina, inhibidores de la proteasa del VIH como ritonavir, antimicóticos azólicos como ketoconazol, digoxina, quinidina, tacrolimus) o inductores, como antiepilépticos (p. ej., fenitoína, carbamazepina y fenobarbitona) o rifampicina.
-Tratamiento concomitante con diuréticos ahorradores de potasio.
-Hipertensión arterial maligna, grave o idiopática lábil, hipotensión ortostática.
-Choque cardiovascular.
-Evidencia de una forma secundaria de hipertensión, como coartación aórtica, hiperaldosteronismo, estenosis de la arteria renal o focromocitoma.
-Infarto de miocardio o angina inestable en los 12 meses previos.
-Valvulopatía cardiaca grave.
-Trastornos graves del ritmo y de la conducción:
       -Bradicardia en la exploración física en reposo(FC< 50/min).
       -Taquicardia en la exploración física en reposo (FC > 100/min). 
       -Arritmias ventriculares complejas frecuentes.
       -Fibrilación auricular.
       -Trastornos de la conducción intraventricular, síndrome de Wolf-Parkinson-White.
       -Bloqueo senoauricular ,bloqueo A-V de segundo o tercer grado.
       -QTc basal > 450 mseg.
-Acontecimiento isquémico cerebrovascular (accidente vascular cerebral,              accidente isquémico transitorio) en los 12 meses previos. 
-Antecedentes de hemorragia intracerebral o hemorragia subaracnoide en los 12 meses previos.  
-Diabetes mellitus tipo I.
-Proteinuría (determinada por Uristix).
-IMC> 34.
-Hipopotasemía o hiperpotasemia no corregidas, con potasio fuera del rango de 3.0 a 5.5 mmol/l.
-Hipernatremia y/o hipovolemia.
-Enfermedad gastrointestinal que provoque una posible mala absorción.
-Estrechamiento grave del tracto gastrointestinal.
-Reservorio de Kock (ileostomía tras proctocolectomía).
-Colestasis o obstrucción biliar.
-Hepatopatía o transaminasemia (AST, ALT) > 3 x el límite superior normal.
-Insuficiencia renal, creatinina > 2.0 mg/dl.
-Cualquier neoplasía maligna que haya requerido el tratamiento en los últimos 5 años.
-Demencia o psicosis.
-Antecedentes de falta de cumplimiento, alcoholismo o toxicomanía.
-Tratamiento con cualquier producto en fase de investigación durante los 30 días anteriores a la Visita 1.
-Embarazo o lactancia.
-Alergia o hipersensibilidad conocida a nifedipino o a cualquier otro calcioantagonista dihidropiridinico o a telmisartan.
-Cualquier trastorno quirúrgico o médico que, a discreción del investigador, ponga al sujeto en riesgo por su participación en el estudio o que puedan impedir al sujeto cumplir con los requerimientos del estudio o completar el período de estudio
-Antecedentes de falta de  cumplimiento con los  tratamientos médicos o sujetos que no estén dispuestos a cumplir con el protocolo del estudio.

E.5 End points
E.5.1 Primary end point(s): La variable primaria de eficacia será la PA sistólica media de 24 horas registrado con MAPA en la  semana 16 de tratamiento en comparación con  el momento basal. 

E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: Information not present in EudraCT
E.6.2 Prophylaxis: Information not present in EudraCT
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: Information not present in EudraCT
E.6.7 Pharmacodynamic: Information not present in EudraCT
E.6.8 Bioequivalence: Information not present in EudraCT
E.6.9 Dose response: Information not present in EudraCT
E.6.10 Pharmacogenetic: Information not present in EudraCT
E.6.11 Pharmacogenomic: Information not present in EudraCT
E.6.12 Pharmacoeconomic: Information not present in EudraCT
E.6.13 Others: Information not present in EudraCT
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): Information not present in EudraCT
E.7.1.1 First administration to humans: Information not present in EudraCT
E.7.1.2 Bioequivalence study: Information not present in EudraCT
E.7.1.3 Other: Information not present in EudraCT
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): Information not present in EudraCT
E.7.3 Therapeutic confirmatory (Phase III): Information not present in EudraCT
E.7.4 Therapeutic use (Phase IV): Yes
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: Yes
E.8.1.3 Single blind: Information not present in EudraCT
E.8.1.4 Double blind: Yes
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: Information not present in EudraCT
E.8.1.7 Other: Yes
E.8.1.7.1 Other trial design description: 16 semanas doble ciego con una ampliación adicional opcional abierta de 8 semanas
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: No
E.8.2.3 Other: Yes
E.8.2.3.1 Comparator description: terapia combinada comparada con monoterapia
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.4.1 Number of sites anticipated in Member State concerned: 10
E.8.5 The trial involves multiple Member States: Yes
E.8.5.1 Number of sites anticipated in the EEA: 39
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: No
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: 
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 1
E.8.9.1 In the Member State concerned months: 3
E.8.9.1 In the Member State concerned days: 0
E.8.9.2 In all countries concerned by the trial years: 1
E.8.9.2 In all countries concerned by the trial months: 3
E.8.9.2 In all countries concerned by the trial days: 0

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: No
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): No
F.1.1.3 Newborns (0-27 days): No
F.1.1.4 Infants and toddlers (28 days-23 months): No
F.1.1.5 Children (2-11years): No
F.1.1.6 Adolescents (12-17 years): No
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Yes
F.3.3.1 Women of childbearing potential not using contraception : No
F.3.3.2 Women of child-bearing potential using contraception: Yes
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 110
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 450
F.4.2.2 In the whole clinical trial: 450

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2007-09-12
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2007-08-02

P. End of Trial
P. End of Trial Status: Completed
P. Date of the global end of the trial: 2009-11-06

